The balance sheet is conservatively leveraged with a debt-to-equity ratio of 0.02, but the asset base has shrunk by 44% from $623.2M in 2024Q1 to $302.6M in 2026Q2 due to sustained cash consumption.
Prothena Corporation plc (PRTA) balance sheet — 16-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|
| Total Current Assets | 292.01M | 315.19M | 485.41M | 639.28M | 719.1M | 584.81M | 299.28M | 378.38M | 431.39M | 426.33M | 391.36M | 377.4M | 299.27M | 178.22M | 125.84M | 124K | 0 |
| Cash & Short-Term Investments | 288.19M | 307.53M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M | 375.72M | 427.66M | 417.62M | 386.92M | 370.59M | 293.58M | 176.68M | 124.86M | 0 | 0 |
| Cash Only | 288.19M | 307.53M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M | 375.72M | 427.66M | 417.62M | 386.92M | 370.59M | 293.58M | 176.68M | 124.86M | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 5.16M | 62K | 13K | 15K | 68K | 2K | 240K | 178K | 509K | 1.76M | 58K | 223K | 0 | 0 |
| Days Sales Outstanding | - | - | - | 20.61 | 0.42 | 0.02 | 6.42 | 30.49 | 0.76 | 3.18 | 61.58 | 115.61 | 12.63 | 31.32 | 30.62 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -240K | -178K | -509K | -1.76M | -58K | -223K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.82M | 1.75M | 1.17M | 3.49M | 1.71M | 766K | 1.35M | 0 | 0 | 0 | 0 | 0 | 0 | 81K | 73K | 0 | 0 |
| Total Non-Current Assets | 10.57M | 11.61M | 61.7M | 57.1M | 38.94M | 24.56M | 33.69M | 40.89M | 67.41M | 70M | 68.61M | 7.83M | 4.84M | 4.19M | 3.44M | 3.49M | 3.3M |
| Property, Plant & Equipment | 9.22M | 10.27M | 13.79M | 16M | 8.01M | 14.13M | 20.36M | 27.15M | 52.84M | 54.99M | 56.45M | 3.86M | 3.12M | 3.37M | 3.39M | 2.54M | 2.4M |
| Fixed Asset Turnover | 5.43x | 0.94x | 9.80x | 5.71x | 6.73x | 14.19x | 0.04x | 0.03x | 0.02x | 0.50x | 0.02x | 0.42x | 16.29x | 0.20x | 0.78x | 0.20x | 0.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49K | 70K | 0 |
| Long-Term Investments | 3.44M | 860K | 860K | 0 | 0 | 0 | 0 | 0 | 4.06M | 4.06M | 4.06M | 0 | 0 | 0 | -122K | 0 | 0 |
| Other Non-Current Assets | 482K | 482K | 3.81M | 7.21M | 12.72M | 3.35M | 1.69M | 3.79M | 4.87M | 6.9M | 6.25M | 1.12M | 0 | 0 | 49K | 885K | 900K |
| Total Assets | 302.58M | 326.8M | 547.11M | 696.38M | 758.03M | 609.37M | 332.98M | 419.27M | 498.8M | 496.33M | 459.98M | 385.24M | 304.12M | 182.41M | 129.28M | 3.62M | 3.3M |
| Asset Turnover | 0.16x | 0.03x | 0.25x | 0.13x | 0.07x | 0.33x | 0.00x | 0.00x | 0.00x | 0.06x | 0.00x | 0.00x | 0.17x | 0.00x | 0.02x | 0.14x | 0.38x |
| Asset Growth % | -134.57% | -40.27% | -21.44% | -8.13% | 24.4% | 83.01% | -20.58% | -15.94% | 0.5% | 7.9% | 19.4% | 26.67% | 66.72% | 41.09% | 3473.33% | 9.64% | - |
| Total Current Liabilities | 11.66M | 40.84M | 48.5M | 56.89M | 50.15M | 33.45M | 25.85M | 17.71M | 14.93M | 37.37M | 41.08M | 22.22M | 12.04M | 7.41M | 1.74M | 8.4M | 1.8M |
| Accounts Payable | 1.94M | 5.88M | 7.77M | 25.39M | 9.27M | 3.69M | 4.12M | 1.24M | 1.47M | 13.63M | 13.07M | 4.52M | 4.72M | 1.79M | 0 | 380K | 100K |
| Days Payables Outstanding | 67.01 | 579.25 | - | - | - | - | 20.07 | 8.92 | 5.3 | 36.98 | 39.91 | 28.22 | 44.82 | 25.08 | - | - | - |
| Short-Term Debt | 2.96M | 2.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 7.6M | 2.66M | 8.85M | 0 | 11.44M | 7.66M | 0 | 0 | 110.24M | -857K | 363K | 284K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.14M | 29.42M | 1.38M | 2.13M | 503K | 405K | 516K | 322K | 837K | 1.72M | 1.87M | 804K | 725K | 658K | 51K | 288K | 1.2M |
| Current Ratio | 25.05x | 7.72x | 10.01x | 11.24x | 14.34x | 17.48x | 11.58x | 21.36x | 28.90x | 11.41x | 9.53x | 16.99x | 24.86x | 24.06x | 72.16x | 0.01x | - |
| Quick Ratio | 25.05x | 7.72x | 10.01x | 11.24x | 14.34x | 17.48x | 11.58x | 21.36x | 28.90x | 11.41x | 9.53x | 17.01x | 25.00x | 24.07x | 72.28x | 0.01x | - |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.03M | 5.49M | 11.68M | 78.13M | 85.85M | 109.87M | 123.12M | 128.63M | 160.87M | 51.77M | 53.5M | 2.35M | 2.19M | 1.73M | 1.05M | 1.65M | 1.4M |
| Long-Term Debt | 0 | 5.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 15.72M | 5.49M | 8.23M | 10.72M | 0 | 6.39M | 12.33M | 17.84M | 49.9M | 51.52M | 51.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -49.9M | -254K | -2.08M | 0 | 1.72M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | -5.49M | 0 | 0 | 553K | 553K | 553K | 553K | 110.97M | 254K | 2.18M | 2.35M | 468K | 1.73M | 1.05M | 1.65M | 0 |
| Total Liabilities | 15.69M | 46.33M | 60.18M | 135.02M | 135.99M | 143.32M | 148.97M | 146.35M | 175.8M | 89.14M | 94.57M | 24.57M | 14.23M | 9.14M | 2.8M | 10.05M | 3.2M |
| Total Debt | 6.99M | 13.86M | 10.84M | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M | 51.55M | 52.25M | 51.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -281.2M | -293.67M | -460.55M | -607M | -703.93M | -566.77M | -277.54M | -352.78M | -376.11M | -365.37M | -335.6M | -370.59M | -293.58M | -176.68M | -124.86M | 0 | 0 |
| Debt / Equity | 0.02x | 0.05x | 0.02x | 0.02x | 0.01x | 0.03x | 0.10x | 0.08x | 0.16x | 0.13x | 0.14x | - | - | - | - | - | - |
| Debt / EBITDA | -0.12x | - | - | - | - | 0.17x | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 4.66x | - | - | - | - | -7.75x | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -41.23x | -41.73x | -184.20x | - | - | - | - | - | - |
| Total Equity | 286.89M | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M | 323M | 407.19M | 365.4M | 360.67M | 289.89M | 173.27M | 126.48M | -6.44M | 100K |
| Equity Growth % | -127.31% | -42.4% | -13.26% | -9.75% | 33.47% | 153.28% | -32.58% | -15.5% | -20.68% | 11.44% | 1.31% | 24.42% | 67.3% | 36.99% | 2065.26% | -6536% | - |
| Book Value per Share | 5.50 | 5.21 | 9.06 | 10.55 | 13.13 | 9.62 | 4.61 | 6.84 | 8.16 | 10.81 | 10.64 | 11.89 | 11.75 | 9.31 | 8.67 | -0.36 | 0.01 |
| Total Shareholders' Equity | 286.89M | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M | 323M | 407.19M | 365.4M | 360.67M | 289.89M | 173.27M | 126.48M | -6.44M | 100K |
| Common Stock | 517K | 538K | 538K | 537K | 521K | 466K | 399K | 399K | 399K | 385K | 348K | 317K | 274K | 219K | 177K | 0 | 0 |
| Retained Earnings | -1.33B | -1.35B | -1.1B | -980.03M | -833M | -716.05M | -783.03M | -671.88M | -598M | -442.35M | -289.21M | -129.1M | -48.49M | -41.34M | -345K | 0 | -12.5M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.5M | -7.74M | -7.67M | -5.34M | -4.71M | -4.29M | -3.71M | -568K | 12.6M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying PRTA stock.
As of 2025, Prothena Corporation plc (PRTA) had total assets of $326.8M including $315.2M in current assets.
Prothena Corporation plc (PRTA) carries total debt of $13.9M, offset by $307.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Prothena Corporation plc (PRTA) has total shareholders' equity (book value) of $280.5M ($5.21 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Prothena Corporation plc (PRTA) reported a current ratio of 7.72x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Sustained cash burn without profitability
Metrics are mathematically derived from official filings.
Asset Base Shrinking from Cash Burn
Total assets have declined by 44% from $623.2M in 2024Q1 to $302.6M in 2026Q2, a trend driven by the consistent consumption of cash reserves to fund operations and share repurchases, as reported in the company's financial statements.
The balance sheet trajectory is one of steady contraction, with the asset base shrinking each quarter as cash is deployed to cover operating losses and buybacks. This pattern suggests the company is in a phase of capital consumption, relying on its existing cash pile rather than generating new capital from operations. The shrinking asset base, absent a corresponding reduction in liabilities, indicates a business model that is currently eroding its financial cushion.
Cash Cushion Eroding but Still Substantial
Despite a 48% reduction in cash from $546.5M in 2024Q1 to $288.2M in 2026Q2, Prothena maintains an exceptionally high current ratio of 25.05, suggesting a significant, though diminishing, buffer against near-term liquidity shocks.
The company's liquidity position remains strong on a static basis, with cash representing over 95% of total assets. However, the trajectory is concerning, as the cash balance has been drawn down by approximately $258M over ten quarters to fund persistent operating losses and share repurchases. The current ratio, while extremely high, is a function of minimal current liabilities, and its sustainability depends entirely on the pace of future cash consumption.
Equity Eroded by Persistent Accumulated Deficit
Shareholders' equity has decreased from $502.4M to $286.9M over the last ten quarters, driven by an accumulated deficit that has deepened to -$1.3B, a figure that underscores the company's history of unprofitable operations.
The equity base is being steadily eroded by net losses, which have accumulated into a massive deficit. This structural weakness is partially offset by the company's large cash position, but the trend indicates that without a path to profitability, equity will continue to decline. The negative retained earnings balance is a clear signal that the business has historically consumed more capital than it has generated.
Cash Burn vs. Shareholder Returns Conflict
The company spent $15.6M on share repurchases in 2026Q2 alone while reporting a net loss of $18.6M, a capital allocation choice that appears misaligned with its status as a cash-burning, pre-profit biotech firm.
The most significant balance sheet distortion is the apparent conflict between the company's operational cash burn and its use of capital for share repurchases. This strategy may be intended to offset dilution from stock-based compensation, but it accelerates the depletion of the cash runway without contributing to operational growth. Investors should monitor whether this capital allocation continues as the cash balance declines, as it could force a future financing event.